CERE — Cerevel Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 62 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
Brief: Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease
Cerevel rises as Parkinson's drug improves symptom control in late-stage trial
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study (updated)
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study
Moody's says pharma outlook turns 'positive' on GLP-1 drug push
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports (updated)
Abbvie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports
Cerevel Therapeutics Holdings Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77
U.S. RESEARCH ROUNDUP- Cerevel Therapeutics, Cytokinetics, Karuna Therapeutics
U.S. RESEARCH ROUNDUP- Atlassian Corp, Broadcom, Cerevel Therapeutics Holdings
U.S. STOCKS ON THE MOVE-Canadian Solar, Domino's, tech stocks
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
Bain scores over tenfold return with $8.7 billion Cerevel sale